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Abstract
Background: Congenital thrombotic risk factors, oncological diseases and its therapies have been
related to an increased occurrence of upper extremities deep venous thrombosis (UEDVT).
Patients and methods: We studied seven patients bearing lymphoma (one Hodgkin's and six
non-Hodgkin's) who developed UEDVT, one at diagnosis and six during chemotherapy (two of
these six cases had implantation of a central venous catheter and four received Growth Colony
Stimulating Factors in addition to chemotherapy). Patients were screened for: factor V G1691A
(Leiden), prothrombin G20210A, methylene tetrahydrofolate reductase (MTHFR) C677T
mutations and antithrombin III, proteins C and S plasma activity.
Results: All patients were wild-type homozygotes for G20210A. One was heterozygote for factor
V G1691A, the other 6 were wild-type homozygotes. Three of the 7 patients were homozygotes
and 2 heterozygotes for the MTHFR mutation; the remaining 2 were wild-type homozygotes.
Clotting inhibitor levels were normal in all patients.
Conclusions: UEDVT in patients bearing haematological malignancies can occur irrespective of
congenital thrombophilic alterations. However, in a subgroup of patients UEDVT could also
depend on congenital thrombophilic alterations. A screening for inherited thrombophilia can
identify high risk patients that could be specifically treated to prevent thrombotic complications.
Introduction
Upper extremities deep venous thrombosis (UEDVT) is
much less frequent than lower extremities deep venous
thrombosis (LEDVT) [1,2]. However, UEDVT is frequent
in patients affected by malignancies and bearing central
venous catheters [3]. Given the association between
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haematological malignancies and acquired throm-
bophilia [4], UEDVT and LEDVT could be a complication
of neoplasia [4,5]. It is known that UEDVT can be trig-
gered by onco-haematological care, i.e., surgery, bed rest,
implantation of a central venous catheter, chemotherapy,
and administration of growth colony stimulating factors
[5]. Inherited thrombotic risk factors could also be present
in several cases, but data on inherited thrombophilic pre-
disposition in patients that develop UEDVT are scarce.
Ruggeri et al. reported a low prevalence of anticoagulant
protein deficiency in patients with UEDVT [6], and Mar-
tinelli et al. found a hypercoagulable state and hyperho-
mocysteinemia nearly in 15% of patients with UEDVT [7].
Prandoni et al. [8] reported a prevalence of 10–26% of
inherited thrombophilic alterations in patients bearing
UEDVT. In an attempt to shed light on the association
between UEDVT, haematological malignancy and con-
genital thrombophilia, we studied three markers of
thrombophilia predisposition, i.e., Factor V G1691A Lei-
den (FVL), the prothrombin G20210A gene mutation
(PTHRA20210G) and the methylene tetrahydrofolate
reductase (MTHFR) C677T gene mutation, as well as the
plasma activity of anticoagulant proteins antithrombin III
(ATIII), protein C (PC) and protein S (PS) in 7 patients
affected by haematological neoplasia and UEDVT, consec-
utively admitted to our observation.
Patients and methods
Patients
In the last year we observed 10 cases of newly diagnosed
UEDVT. We studied 7 selected patients (6 females and 1
male, mean age 37 ± 8 years) bearing UEDVT as compli-
cation of an underlying lymphoproliferative disease; the
other 3 referred patients affected by UEDVT were excluded
because 2 (1 male and 1 female) carrier of a thoracic out-
let syndrome while the third subject, an elderly woman,
was affected by peritoneal metastasis and non-valvular
atrial fibrillation. Of the seven selected patients, one
female was affected by Hodgkin's disease, and six other
patients by non Hodgkin's lymphoma. One patient
showed UEDVT as the presenting sign of non Hodgkin's
lymphoma, whereas six others developed UEDVT during
chemotherapy. Two of these six patients had a central
venous catheter (CVC) implant, four others received
growth colony stimulating factor (G-CSF) during chemo-
therapy; only one patients had both CVC and G-CSF dur-
ing chemotreatment. Six patients had mediastinal
involvement (two bulky), and one had extranodal non
Hodgkin's lymphoma. UEDVT was diagnosed in all
patients by ultrasound imaging with 7–10 Mhz probe
(ATL 1500 HDI, Philips).
Methods
A whole blood sample (5 mL) was collected in EDTA by
venipuncture. DNA was extracted using the "Nucleon
BACC2" kit (Amersham, Germany). Patients were
screened for the following mutations: Factor V gene
G1691A (Leiden), G20210A in the prothrombin gene and
C677T in the MTHFR gene using PCR amplification with
specific primers, and the Light Cycler apparatus (Roche,
Italy). Plasma activity of antithrombin III and protein C
was evaluated with commercial kits (Boehringer, Ger-
many) as was plasma protein S activity (Biopool,
Sweden).
Results and discussion
Results of molecular analysis are reported in Table 1. All 7
patients were wild-type homozygotes for the pro-
thrombin G20210A mutation. One of the 7 was heterozy-
gote for Factor V G1691A (Leiden), the other six being
wild type homozygotes. Three of the 7 patients were
homozygotes for the MTHFR mutation, two were hetero-
zygotes, a condition not associated to higher risk of
thrombophilia [7], and two were wild-type homozygotes.
The plasma activity of AT III, PC and PS was within the ref-
erence intervals (data not shown).
Table 1: Type of neoplasia and thrombophilia risk factor mutations in seven patients bearing upper extremities deep venous 
thrombosis
Patient Sex Age (years) Diagnosis of neoplasia Factor V Leiden 
(G1691A)
PTHRA20210GM T H F R  C 6 7 7 T
1 F 40 Extranodal NHL WT/WT WT/WT WT/WT
2 F 53 NHL WT/WT WT/WT MUT/MUT
3 M 27 NHL WT/WT WT/WT WT/WT
4 F 38 NHL MUT/WT WT/WT MUT/WT
5 F 28 NHL bulky WT/WT WT/WT MUT/MUT
6 M 33 NHL bulky WT/WT WT/WT MUT/MUT
7 F 30 HD WT/WT WT/WT MUT/WT
NHL: non Hodgkin's lymphoma; HD: Hodgkin Disease; WT: wild type allele; MUT: mutated alleleJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/7
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The observations concerning the frequency of UEDVT
increased since the first studies conducted in the 1980s
[9,10] particularly in neoplastic patients as a consequence
of such triggering factors as central venous catheter plant,
chemotherapy, growth colony stimulating factors and
others [3,4,11]. These data agree with our experience in
the last year. Although in this period we examined nearly
90 oncological patients suspected to have a DVT (UEDVT,
LEDVT or both), DVT was confirmed by ultrasound imag-
ing in 30% of these (i.e. 27 patients). Moreover, nearly
67% of diagnosed DVT were LEDVT, while the remaining
33% were UEDVT, so confirming the increased incidence
of UEDVT in oncological patients. Furthermore, in this
report we may also testify an increased UEDVT risk in
oncohaematological patients vs oncological patients
because 7/8 of observed patients showed a lymphoprolif-
erative disease in this particular population. Inherited
alteration of clotting inhibitors (AT III, PC and PS) or
genetic polymorphisms associated to a higher risk of
thrombotic events have been reported in a percentage of
patients with UEDVT ranging between 10 and 26% [6].
Yet our data, although on a preliminary population, indi-
cate that more than 50% of neoplastic patients bearing
UEDVT have altered markers of thrombophilia. Three
patients, in fact, were homozygotes for the MTHFR muta-
tion (42.8% versus 20% reported in the general popula-
tion) and one was heterozygote for the Leiden mutation
(14.7% versus 5.0% reported in the general population)
[12]. On the contrary, none of our patients carried altered
plasma levels of clotting inhibitors, confirming the obser-
vation of Ruggeri on the low prevalence of anticoagulant
protein deficiency in patients with UEDVT [6].
However, our patients did not have a history of throm-
botic events up to our observation. The fact that they
developed UEDVT during chemotherapy for lymphopro-
liferative disorders suggest that the genetic alteration
could act a predisposing factor, and that oncological dis-
ease and its therapy triggered the UEDVT. On the other
hand, 3 patients without mutations in the genes examined
developed UEDVT confirming that also in absence of
inherited predisposition UEDVT can occur in oncological
patients [2,8], so confirming the relevant role as throm-
botic risk factors of malignancies and their care. However,
we cannot exclude the possibility that they may carry
other gene mutations predisposing to thrombophilic
alterations [12].
Six of the seven patients in our study developed UEDVT
during chemotherapy, four of which also received G-CSF
and two had received central venous catheter implant to
simplify administration of chemotherapy, thus confirm-
ing that these factors are strictly related to thrombotic
complications in neoplastic patients [3,8]. Interestingly,
in 6 patients the haematological malignancy showed
mediastinal involvement, in two cases as bulky disease,
which can cause vascular compression. Thus, also medias-
tinal involvement during haematological malignancy
could be a risk factor for UEDVT, possibly mimicking a
condition similar to thoracic outlet syndrome [3].
It must be underlined that UEDVT has been recently asso-
ciated to higher morbidity and mortality for pulmonary
embolism than LEDVT [13]. Furthermore, post-throm-
botic sequelae may follow UEDVT [14]. On the other
hand, specific therapies to prevent UEDVT in neoplastic
patients are available [15].
Conclusions
Venous thromboembolism is a multifactorial disease in
which inherited and acquired risk factors are involved.
UEDVT are less common than LEDVT, but recently other
UEDVT thrombotic risk factors have been identified such
as inherited thrombophilia and plant of central venous
catheters so improving knowledge on UEDVT pathophys-
iology. Although on a preliminary population our data
show the contemporaneousness of inherited and acquired
thrombotic risk factors in UEDVT patients bearing lym-
phoma. In particular, four of seven patients showed
genetic polimorphisms with a trend toward throm-
bophilia and six of seven studied patients showed UEDVT
during chemotherapy so underlying this gene-enviromen-
tal association. Thus, given the high occurrence of throm-
bophilic alterations observed in our population of
UEDVT patients, we suggest to test also molecular markers
of inherited thrombophilia in onco-haematological
patients before chemotherapy in order to consider a pri-
mary thromboprophylaxis for UEDVT, in particular if
other enviromental oncological factors occur, such as
plant of CVC, G-CSF administration and mediastinal
involvement.
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